Stocks | |||||
The table gives an overview of all stocks, alphabetically sorted. | |||||
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z |
Name | Symbol | Analysis date | Close | +/- % |
3SBIO Inc | 83B | Apr 30, 2024 | 0.69 | +1.46 |
Acrux Ltd | FJY | Apr 30, 2024 | 0.05 | +44.62 |
Actinogen Medical Limited | 3AC | Apr 30, 2024 | 0.02 | +16.22 |
Akeso Inc | 4RY | Apr 30, 2024 | 5.70 | -1.72 |
Aligos Therapeutics, Inc. - Common stock | 5WK | Apr 30, 2024 | 0.67 | -6.28 |
Alphamab Oncology (HK) Limited | 3NK | Apr 30, 2024 | 0.55 | -1.80 |
Alterity Therapeutics Ltd | PBN | Apr 30, 2024 | 0.00 | 0.00 |
AnGes Inc. | AJW | Apr 30, 2024 | 0.23 | -3.33 |
Antengene Corporation Limited | 722 | Apr 30, 2024 | 0.10 | +1.06 |
Ascletis Pharma Inc. | 2VJ | Apr 30, 2024 | 0.15 | +11.28 |
Avacta Group Plc | RTQ1 | Apr 30, 2024 | 0.55 | +0.93 |
Avecho Biotechnology Limited | OEZ | Apr 30, 2024 | 0.00 | -71.43 |
BeiGene Ltd | 49B | Apr 30, 2024 | 11.00 | -0.90 |
Biofrontera AG | B8F | Apr 30, 2024 | 0.36 | +23.97 |
Biomed-Lubin Wytwornia Surowic I Szczepionek S.A. | 6NQ | Apr 30, 2024 | 1.07 | +0.95 |
Biophytis | 6XB | Apr 30, 2024 | 0.00 | 0.00 |
Biotest AG | BIO3 | Apr 30, 2024 | 28.70 | +0.70 |
Bioton S.A. | 7U5 | Apr 30, 2024 | 0.79 | +0.13 |
Bioventix Plc | 51B | Apr 30, 2024 | 49.20 | -4.47 |
Bone Therapeutics S.A. | BT1 | Apr 30, 2024 | 0.01 | -1.28 |
C4X Discovery Holdings plc | C4J | Apr 30, 2024 | 0.12 | 0.00 |
Cellectis | ZVA | Apr 30, 2024 | 2.38 | -2.45 |
Celon Pharma SA | 8RP | Apr 30, 2024 | 3.36 | 0.00 |
Chromadex Corp | OCD1 | Apr 30, 2024 | 3.28 | +3.14 |
Circassia Group Plc | 82C | Apr 30, 2024 | 0.80 | +1.27 |
CKLIFE SCIENCES | LSI | Apr 30, 2024 | 0.04 | +7.89 |
Clinuvel Pharmaceuticals Ltd | UR9A | Apr 30, 2024 | 8.95 | -2.19 |
Clinuvel Pharmaceuticals Ltd Ordinary Shares (Australia) | UR9 | Apr 30, 2024 | 8.99 | -5.22 |
Csl Ltd SPONSORED ADR (Australia) | CSJA | Apr 30, 2024 | 83.00 | -0.60 |
CSL Ltd. | CSJ | Apr 30, 2024 | 166.08 | -0.48 |
Investtech guarantees neither the entirety nor accuracy of the analyses. Any consequent exposure related to the advice / signals which emerge in the analyses is completely and entirely at the investors own expense and risk. Investtech is not responsible for any loss, either directly or indirectly, which arises as a result of the use of Investtechs analyses. Details of any arising conflicts of interest will always appear in the investment recommendations. Further information about Investtechs analyses can be found here disclaimer.
The content provided by Investtech.com is NOT SEC or FSA regulated and is therefore not intended for US or UK consumers.
Investtech guarantees neither the entirety nor accuracy of the analyses. Any consequent exposure related to the advice / signals which emerge in the analyses is completely and entirely at the investors own expense and risk. Investtech is not responsible for any loss, either directly or indirectly, which arises as a result of the use of Investtechs analyses. Details of any arising conflicts of interest will always appear in the investment recommendations. Further information about Investtechs analyses can be found here disclaimer.
The content provided by Investtech.com is NOT SEC or FSA regulated and is therefore not intended for US or UK consumers.